doi:10.16150/j.1671-2870.2021.06.015

Abstract

CLC Number:

R735

References 31

[1]	Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma[J]. Blood Cancer J, 2019, 9(4):44. doi: 10.1038/s41408-019-0205-9 pmid: 30962422
[2]	Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma[J]. Dtsch Arztebl Int, 2016, 113(27-28):470-476.
[3]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. doi: 10.3322/caac.21387 URL
[4]	Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096 URL
[5]	Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma[J]. Ther Adv Hematol, 2018, 9(5):123-133. doi: 10.1177/2040620718761776 URL
[6]	Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma[J]. Memo, 2018, 11(1):59-64. doi: 10.1007/s12254-018-0383-3 URL
[7]	van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future[J]. Blood, 2018, 131(1):13-29. doi: 10.1182/blood-2017-06-740944 URL
[8]	Quarona V, Ferri V, Chillemi A, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche[J]. Ann N Y Acad Sci, 2015, 1335:10-22. doi: 10.1111/nyas.12485 URL
[9]	Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38⁺ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma[J]. Blood, 2016, 128(3):384-394. doi: 10.1182/blood-2015-12-687749 pmid: 27222480
[10]	Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology[J]. Physiol Rev, 2008, 88(3):841-886. doi: 10.1152/physrev.00035.2007 pmid: 18626062
[11]	Sherbenou DW, Behrens CR, Su Y, et al. The development of potential antibody-based therapies for myeloma[J]. Blood Rev, 2015, 29(2):81-91. doi: 10.1016/j.blre.2014.09.011 pmid: 25294123
[12]	Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy[J]. Nat Rev Immunol, 2010, 10(5):317-327. doi: 10.1038/nri2744 pmid: 20414205
[13]	de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J]. J Immunol, 2011, 186(3):1840-1848. doi: 10.4049/jimmunol.1003032 URL
[14]	Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer[J]. Nat Rev Cancer, 2012, 12(4):278-87. doi: 10.1038/nrc3236 URL
[15]	Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma[J]. MAbs, 2015, 7(2):311-321. doi: 10.1080/19420862.2015.1007813 pmid: 25760767
[16]	Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking[J]. J Immunol, 2016, 197(3):807-813. doi: 10.4049/jimmunol.1501351 pmid: 27316683
[17]	Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma[J]. J Hematol Oncol, 2016, 9(1):51. doi: 10.1186/s13045-016-0283-0 URL
[18]	van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies[J]. Immunol Lett, 2018, 199:16-22. doi: 10.1016/j.imlet.2018.04.005 URL
[19]	Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma[J]. Front Immunol, 2018, 9:1228. doi: 10.3389/fimmu.2018.01228 pmid: 29915586
[20]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志, 2020, 59(5):341-346.
[21]	Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1 URL
[22]	Lamb YN. Daratumumab: A Review in Combination thera-py for transplant-eligible newly diagnosed multiple myeloma[J]. Drugs, 2020, 80(14):1455-1464. doi: 10.1007/s40265-020-01385-x URL
[23]	Voorhees PM, Kaufman JL, Laubach J, et al. Daratumu-mab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood, 2020, 136(8):936-945. doi: 10.1182/blood.2020005288 pmid: 32325490
[24]	Voorhees P, Rodriguez C, Reeves B, et al. Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Grifin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Muliple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)[J]. Blood, 2018, 132:151. doi: 10.1182/blood-2018-151 URL
[25]	Bal S, Godby K, Chhabra S, et al. Impact of Autologous hematopoetic stem cell transplant (AHCT) on measurable residual disease(MRD) by next generation sequencing (NGS) in the setting of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) quadruplet induction[J]. Biol Blood Marrow Transplant, 2020, 26(3):S24.
[26]	Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3 URL
[27]	Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma[J]. Cancer, 2019, 125(14):2364-2382. doi: 10.1002/cncr.32065 pmid: 30951198
[28]	Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22):2104-2115. doi: 10.1056/NEJMoa1817249 URL
[29]	郭怀鹏, 康蕾, 刘聪, 等. Daratumumab在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta分析[J]. 临床血液学杂志, 2021, 34(11):795-801,806.
[30]	刘进, 何海燕, 李璐, 等. 达雷妥尤单抗治疗复发/难治多发性骨髓瘤的疗效与安全性[J]. 中华血液学杂志, 2021, 42(1):27-32.
[31]	Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumu-mab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 78(6):518-528.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 551-554.
[2]	ZHOU Sifeng, XU Haishu, FAN Xinsheng. Application of metabolomics of different biological samples in study of OSAHS biomarkers [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 535-540.
[3]	XIONG Xinhai, LI Jia, DING Xiaosong, JI Congcong, SHI Hourong, XIANG Minjie. Leishmaniasis with secondary hemophagocytic syndrome: a case report [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 524-526.
[4]	BAO Zhiyao, MENG Wenkai, SHEN Jimin, LI Qingyun. Hematogenous disseminated pneumonia secondary to suppurative tonsillitis in adults: a case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 520-523.
[5]	LI Lei, YUAN Fei, WANG Chaofu, XU Haimin, WANG Ting. Ampullary adenocarcinoma: analysis of the clinicopathological features and prognostic factors [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 355-361.
[6]	GUO Yebing, ZHENG Jinfeng. The extra-gastrointestinal stromal tumors located in vagina: A case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 405-407.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 102-104.
[8]	HUANG Pei, REN Rujing, PAN Yu, LIN Guozhen, WANG Gang. Early-onset Alzheimer′s disease complicated with cerebral amyloid angiopathy: A case report [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 86-89.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 99-101.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 529-532.
[11]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 582-583.
[12]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 584-587.
[13]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 596-598.
[14]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 512-514.
[15]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 507-511.